About Affymax
Affymax is a publicly listed company based in Palo Alto (United States) founded in 2001. Drug for treatment of chronic kidney disease. Affymax has raised $131 million across 4 funding rounds from investors including Credit Suisse, Apax Partners and Bear Stearns Companies. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Renal Disorders. Its legal entity is AFFYMAX INC. Its competitors include Unicycive, Peloton Therapeutics and Angion Biomedica; 3 of its 3 listed competitors have raised funding.
Company details
Affymax is a biopharmaceutical company developing drugs to improve the treatment of serious and often life-threatening conditions. The companys first product candidate, peginesatide (formerly known as Hematide), has been investigated in Phase 3 trials for the potential treatment of anemia associated with chronic kidney disease (CKD). The company went public on December 15, 2006. The company has now shut its operations.
- Headquarters Palo Alto, United States
- Stage Public
- SectorsHealthcare
- Website affymax.com
- Social LinkedIn
- Legal Name Affymax Inc
- Total Equity Funding$131M (USD)
in 4 rounds
- Latest Funding Round$42M (USD), Post-IPO
Mar 2009
- InvestorsCredit Suisse
& 3 more
Funding Insights of Affymax
Affymax has successfully raised a total of $131M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $42 million completed in March 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $131M
- Total Rounds 4
- Last Round Post-IPO — $42M
- First Round $51M
(Jul 2001)
- Investors Count 4
All 4 funding rounds of Affymax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2009 | $42M | Post-IPO | – | – | – |
| Jul 2005 | $60M | Private Equity Round | – | – | – |
| Apr 2004 | $20M | Series C | – | – | |
| Jul 2001 | $51M | Private Equity Round | – | – |
4 investors in total: 4 institutional.
Investors in Affymax
Affymax has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Credit Suisse, Apax Partners and Bear Stearns Companies.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Equity investments are focused on tech, services, and consumer sectors. | 1981 | apax.com | Hong Kong, China | |
Investment and wealth planning services are provided to clients. | 1995 | bearstearns.com | New York, United States | |
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Wealth management, asset management, and investment banking services are offered. | 1856 | credit-suisse.com | Zurich, Switzerland |
Investor details for Affymax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Affymax
Affymax is a publicly listed company on the OTC with ticker symbol AFFY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Jun 2013
- Listed onOTCMKTS: AFFY
- Listed entityAFFYMAX INC
- Exchange sectorHealth technology
- ISINUS00826A1097
- Share price$0.04 (+2347.06% on the day) · 2026-10-09
- Market capitalisation$1.6M
- Volume (last session)1,000
Timeline of Affymax
4 dated milestones of Affymax across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Affymax is founded.
- Funding First funding round of $51.0M.
- Funding Latest funding round, Post-IPO, of $42.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Affymax
Affymax has 3 listed competitors in our database, 3 of them funded. They include Unicycive, Peloton Therapeutics and Angion Biomedica.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| unicycive.com | 2016 | San Francisco, United States | $1.55M | 12 | Small molecule therapies for kidney diseases are developed. | |
| pelotontherapeutics.com | 2010 | Dallas, United States | $242.6M | 62 | Small molecule therapeutics for kidney cancer are developed. | |
| angion.com | 1998 | United States | $73.95M | 71 | Organ restoration therapies for renal diseases are developed. |
Detailed competitors of Affymax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Affymax
Websites that share an audience with Affymax (affymax.com).
Websites whose visitors overlap most with Affymax. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
nanotherapeutics.com | nanotherapeutics.com | 100% | – | ||
chemovation.com | chemovation.com | 100% | – | ||
| cytomyx.com | 100% | View details | |||
| prosidion.com | 100% | View details | |||
| biotrondiagnostics.com | 100% | 1.5K | #9,362,675 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 27 similar websites and full traffic analytics for Affymax
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 27 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Affymax (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Affymax
Complete news archive for Affymax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Affymax
Affymax was founded in 2001.
Affymax is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Affymax is a funded company, having raised a total of $131M across 4 funding rounds to date. The company's 1st funding round was a Private Equity Round of $51M, raised on Jul 2001.
Affymax is a biopharmaceutical company developing drugs to improve the treatment of serious and often life-threatening conditions. The companys first product candidate, peginesatide (formerly known as Hematide), has been investigated in Phase 3 trials for the potential treatment of anemia associated with chronic kidney disease (CKD). The company went public on December 15, 2006. The company has now shut its operations.
Affymax's top competitors include Unicycive, Peloton Therapeutics and Angion Biomedica.
Yes, Affymax is publicly traded on OTC under the ticker symbol AFFY.
Affymax has 4 investors. Key investors include Credit Suisse, Apax Partners, Bear Stearns Companies, and Turmeric Acquisition Corp.
Affymax operates through Affymax Inc.